Telix Pharmaceuticals Ltd., of Melbourne, Australia, and Genesiscare Pty Ltd., a provider of cancer and cardiac services, were cleared to start the Enhancing study, a phase II imaging study comparing the expression of prostate-specific membrane antigen, before and after treatment with Xtandi (enzalutamide, Astellas Pharma Inc.), using PET.